Shield Therapeutics (LSE:STX) reported strong first-half revenue growth and a substantially reduced loss as increasing ACCRUFeR® sales in the US and higher international milestone and royalty income moved the company closer to operating profitability.
Unaudited group revenue for the first half of 2026 reached $30.4 million, an increase of 42% from the same period last year. Growth was supported by continued demand for ACCRUFeR® in the US alongside a significant increase in milestone payments and royalties generated from markets outside the country.
The group’s loss narrowed to $2.3 million as higher revenue combined with a more streamlined cost base. Shield said the improvement keeps it on track with its objective of reaching operating profitability during 2026.
US prescriptions for ACCRUFeR® increased 21% year-on-year to approximately 102,000 despite a substantial reduction in approvals from New York Medicaid. Shield responded by shifting its commercial emphasis towards patients covered by private insurance, helping mitigate the impact of the Medicaid changes.
The company also secured its first contract with a group purchasing organisation, providing another potential channel through which to broaden access to ACCRUFeR® and support future prescription growth.
Progress continued internationally, with paediatric indication extensions for ACCRUFeR®/FeRACCRU® across the US, Europe and the UK widening the potential patient population. Shield also received a significant milestone payment from its Chinese partner ASK Pharma, while clinical development activities in Japan continued to advance.
Together, these developments are expanding the global commercial platform for Shield’s oral iron treatment and increasing the contribution from licensing partnerships alongside direct US sales.
The appointment of a new Chief Financial Officer further reinforces management’s focus on financial execution as the company works towards sustainable profitability and seeks to capitalise on growing demand for ACCRUFeR®.
Despite the improvement in trading, Shield’s financial resilience remains a key risk. The company continues to report losses and cash outflows and has negative equity, leaving its financial position vulnerable even as revenue and margins improve.
Technical indicators are also weak, with the shares in a pronounced downtrend and momentum remaining negative. Valuation offers limited support while the company remains unprofitable, and the absence of a dividend means there is currently no income component to the investment case.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company focused on treatments for iron deficiency and iron deficiency anaemia. Its principal product is ACCRUFeR®/FeRACCRU® (ferric maltol), a prescription oral iron therapy.
In the US, ACCRUFeR® is commercialised through an exclusive collaboration with Viatris Inc., while FeRACCRU® has been licensed to partners covering markets including Europe, the UK, Canada, China, Japan and Korea.
The company estimates that around 20 million people in the US are affected by iron deficiency, representing a potential market opportunity of approximately $2.3 billion. ACCRUFeR®/FeRACCRU® benefits from patent protection extending into the mid-2030s, while its differentiated non-salt formulation and tolerability profile underpin Shield’s strategy of establishing the treatment as a leading prescription oral iron option.
Focus keyphrase: Shield Therapeutics H1 2026 results
Meta description: Shield Therapeutics reports a 42% rise in H1 revenue to $30.4 million as ACCRUFeR growth and international milestones help narrow its loss to $2.3 million.
Leave a Reply